Changeflow GovPing Pharma & Drug Safety EP4139921A1 - Method and System for Identifying...
Routine Notice Added Final

EP4139921A1 - Method and System for Identifying Candidate Immunogenic Protein Regions for Vaccine Development

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published application EP4139921A1 for NEC OncoImmunity AS, covering a computational method and system for identifying candidate regions of source proteins predicted to instigate an immunogenic response. The invention has applications in vaccine development and creates enforceable patent rights across 36 designated European member states.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The EPO published European patent application EP4139921A1 for NEC OncoImmunity AS, covering a method and system for identifying candidate regions of source proteins predicted to instigate an immunogenic response, and methods for creating vaccines based on such identification. The application includes IPC classifications in bioinformatics (G16B), pharmaceutical compositions (A61K), and antiviral agents (A61P).

This patent grant creates enforceable intellectual property rights for the applicant across 36 designated European contracting states, including AT, BE, CH, DE, DK, ES, FI, FR, GB, IT, NL, NO, PL, SE, and others. Third parties may seek to oppose the grant within nine months of publication under EPO opposition procedures.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

METHOD AND SYSTEM FOR IDENTIFYING ONE OR MORE CANDIDATE REGIONS OF ONE OR MORE SOURCE PROTEINS THAT ARE PREDICTED TO INSTIGATE AN IMMUNOGENIC RESPONSE, AND METHOD FOR CREATING A VACCINE

Publication EP4139921A1 Kind: A1 Apr 08, 2026

Applicants

NEC OncoImmunity AS

Inventors

SIMOVSKI, Boris, MOLINÉ, Clément, STRATFORD, Richard, CLANCY, Trevor

IPC Classifications

G16B 15/30 20190101AFI20211029BHEP A61K 39/00 20060101ALI20211029BHEP G16B 30/00 20190101ALI20211029BHEP A61K 39/12 20060101ALI20211029BHEP A61P 31/14 20060101ALI20211029BHEP C12N 7/00 20060101ALI20211029BHEP G16H 50/50 20180101ALI20211029BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4139921A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254.1 Biotechnology
Activity scope
Patent granting Immunogenic protein identification Vaccine development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!